iSpecimen (ISPC) Registration filing summary

Company overview and business model

• Operates a technology-driven online marketplace connecting life science researchers with healthcare providers for the procurement of human biospecimens and associated data, aiming to streamline and scale the biospecimen supply chain globally.

• Revenue is generated by sourcing specimens from a network of 55+ healthcare organizations in 14 countries and distributing them to research clients, with revenue sharing back to suppliers.

• Products include remnant and research-use-only biofluids, tissues, and hematopoietic stem and immune cells, with a focus on just-in-time procurement rather than inventory banking.

• Customers include biopharmaceutical, in vitro diagnostic, and government/academic institutions, with over 219,000 specimens distributed to 23 countries as of March 31, 2026.

• The platform is being modernized to enhance automation, data integration, and scalability, with ongoing investments in technology and operational efficiency.

Financial performance and metrics

• Reported net losses of $10.5 million in 2025 and $12.5 million in 2024, with an accumulated deficit of $84.6 million as of March 31, 2026.

• Revenue for the three months ended March 31, 2026 was $1.93 million, compared to $2.69 million for the same period in 2025.

• Cash balance as of March 31, 2026 was $2.8 million, with working capital of $814,038.

• Revenue is highly concentrated, with one customer accounting for 54% of revenue in Q1 2026 and 20% in 2025.

• The company is not currently profitable and expects to continue incurring losses for the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for placement agent fees, offering expenses, debt repayment, potential acquisitions, marketing (up to $1 million to IR Agency LLC), and general corporate and working capital purposes.

• Management has broad discretion over the allocation of proceeds, and actual use may vary depending on business needs and market conditions.